We covered this research earlier, when it first was published, here: Canagliflozin - Another Top Longevity Drug - #1818 by RapAdmin
A new story on it here:
Henagliflozin, a diabetes treatment approved in China, may do more than just control blood sugar—it may actually slow biological aging. Long prescribed to patients with type 2 diabetes to manage glucose, this drug is now drawing attention after clinical trials in China revealed measurable shifts in blood markers and cellular function linked to slower aging. These findings position henagliflozin at the intersection of diabetes care and longevity science. They are raising both optimism and debate over whether existing medications might also serve as anti-aging therapies.
Aging and diabetes often go hand in hand. High blood sugar can harm the body over time, leading to inflammation and accelerated aging. To understand this connection, research now uses “biomarkers”—simple measurements like telomere length and immune cell health—to track aging in people with chronic illnesses like diabetes. These markers help researchers figure out whether treatments are slowing the aging process.
Inside the Henagliflozin Study
The latest study on henagliflozin included 150 adults with type 2 diabetes who participated in a 26-week trial. The participants were split into two groups. One group received daily henagliflozin pills, and the other got a placebo. Everyone followed similar diet and exercise advice, so the focus was on whether henagliflozin made a real difference.
Results from the trial were promising. People on henagliflozin generally had longer telomeres after 26 weeks, suggesting a slower aging process. Those in the placebo group did not experience significant changes. The drug also boosted levels of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a protein important for cell repair and growth. Specifically, the protein regulates mitochondrial function and promotes efficient energy metabolism.